The First Argentine Consensus on the use of testosterone in postmenopausal women
Article Sidebar
Main Article Content
Abstract
The First Argentine Consensus on the use of testosterone in postmenopausal women is presented, developed by a multidisciplinary panel of 31 specialists using Delphi methodology. Indications, contraindications, dosing, formulations, and clinical monitoring of female androgen therapy are analyzed. It is established that the only evidence-based indication is hypoactive sexual desire disorder (HSDD) in postmenopausal women with confirmed clinical diagnosis. Transdermal formulations at physiological doses are recommended, while oral, intramuscular, and subcutaneous implant routes are discouraged. Levels of evidence and grades of recommendation are classified according to international standards. The document promotes responsible, evidence-based medical prescribing, free from commercial bias and adapted to the Argentine clinical context.
Downloads
Article Details
How to Cite
References
Achilli, C., Pundir, J., Ramanathan, P. B., Sabatini, L., Hamoda, H., & Panay, N. (2017). Efficacy and safety of trans-dermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertility and Sterility, 107(2), 475–482.e15. https://doi.org/10.1016/j.fertnstert.2016.10.028
Clayton, A. H., Goldstein, I., Kim, N. N., Althof, S. E., Faubion, S. S., Faught, B. M., Parish, S. J., Simon, J. A., Vignozzi, L., & Warnock, J. K. (2018). The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. Mayo Clinic Proceedings, 93(4), 467–487. https://doi.org/10.1016/j.mayocp.2017.11.002
Davis, S. R., Baber, R., Panay, N., Bitzer, J., Perez, S. C., Islam, R. M., Kaunitz, A. M., Kingsberg, S. A., Lambrinoudaki, I., Liu, J., Parish, S. J., Pinkerton, J., Rymer, J., Simon, J. A., Vignozzi, L., & Wierman, M. E. (2019). Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology & Metabolism, 104(10), 4660–4666. https://doi.org/10.1210/jc.2019-01603
Elraiyah, T., Sonbol, M. B., Wang, Z., Khairalseed, T., Asi, N., Undavalli, C., Nabhan, M., Altayar, O., Prokop, L., Montori, V. M., & Murad, M. H. (2014). The benefits and harms of sys-temic testosterone therapy in postmeno-pausal women with normal adrenal function: a systematic review and meta-analysis. Journal of Clinical Endocri-nology & Metabolism, 99(10), 3543–3550. https://doi.org/10.1210/jc.2014-2262
Islam, R. M., Bell, R. J., Green, S., Page, M. J., & Davis, S. R. (2019). Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes & Endocrinolo-gy, 7(10), 754–766. https://doi.org/10.1016/S2213-8587(19)30189-5
Parish, S. J., Simon, J. A., Davis, S. R., Giraldi, A., Goldstein, I., Goldstein, S. W., Kim, N. N., Kingsberg, S. A., Morgentaler, A., Nappi, R. E., Park, K., Stuenkel, C. A., Traish, A. M., & Vignozzi, L. (2021). International Soci-ety for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Climacteric, 24(6), 533–550. https://doi.org/10.1080/13697137.2021.1891773
Ribera Torres, L., Anglès-Acedo, S., López-Chardi, L., Mension Coll, E., & Castelo-Branco, C. (2024). Systemic testosterone for the treatment of female sexual interest and arousal disorder (FSIAD) in the postmenopause. Gyne-cological Endocrinology, 40(1), e2364220. https://doi.org/10.1080/09513590.2024.2364220
Taylor, B., & Davis, S. (2006). Using the extended PLISSIT model to address sexual healthcare needs. Nursing Stan-dard, 21(11), 35–40. https://doi.org/10.7748/ns2006.11.21.11.35.c6380